Related Experiment Video
Updated: Dec 31, 2025
Spontaneous Murine Model of Anaplastic Thyroid Cancer
Published on: February 3, 2023
[SMARCA4-deficient thoracic tumors: A new entity]
Elise Decroix1, Karen Leroy2, Marie Wislez3
1Cordeliers Research Center, « Immune Control and Escape », unité Inserm UMRS 1138, Paris, France; AP-HP, Université Paris Descartes, hôpital Cochin, département de pathologie, service d'anatomie pathologique, HUPC, 27, rue du faubourg Saint-Jacques, 74014 Paris, France.
Abstract:
A growing number of studies suggest a tumor suppressor role for the SWI/SNF complex involved in the remodeling of chromatin. Alterations of this complex have been found in many tumors of different origins, with topographic, morphologic and phenotypic diversity. Notably, they define 2 types of thoracic tumors: SMARCA4-deficient non-small cell lung carcinoma and SMARCA4-deficient sarcoma. Some clinical features appear to be common to both, such as intrathoracic localization, smoking exposure, male predominance and poor prognosis. However, the histological distinction between these two entities is sometimes difficult and it is not excluded that these entities belong to the same tumor spectrum with different degrees of differentiation. The therapy of these tumors is not yet codified. These tumors do not seem associated with oncogenic driver mutations allowing the prescription of targeted therapy, but immunotherapy has been shown to be effective in rare reported cases. More specific treatments using EZH2 inhibitors also seem promising in SMARCA4 deficient sarcomas.
Insights
SWI/SNF complex alterations are linked to thoracic tumors like SMARCA4-deficient lung cancer and sarcoma. These tumors share clinical traits, but treatment options remain limited, with immunotherapy showing promise.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- The SWI/SNF complex plays a crucial role in chromatin remodeling and acts as a tumor suppressor.
- Alterations in the SWI/SNF complex are observed in various cancers, including specific thoracic tumors.
- SMARCA4-deficient non-small cell lung carcinoma and SMARCA4-deficient sarcoma represent distinct thoracic malignancies associated with SWI/SNF complex alterations.
Purpose of the Study:
- To investigate the tumor suppressor role of the SWI/SNF complex.
- To characterize SMARCA4-deficient thoracic tumors, including their clinical and pathological features.
- To explore potential therapeutic strategies for these rare malignancies.
Main Methods:
- Review of existing studies on SWI/SNF complex alterations in cancer.
- Comparative analysis of clinical and morphological features of SMARCA4-deficient lung carcinoma and sarcoma.
- Evaluation of current and potential treatment modalities.
Main Results:
- SMARCA4-deficient thoracic tumors exhibit common features like intrathoracic localization, smoking history, male predominance, and poor prognosis.
- Histological differentiation between these tumor types can be challenging, suggesting a potential spectrum.
- Targeted therapies are limited due to lack of common driver mutations, but immunotherapy shows efficacy in some cases.
Conclusions:
- SMARCA4-deficient thoracic tumors represent a challenging group of malignancies with overlapping features.
- Further research is needed to clarify their exact relationship and establish standardized therapeutic protocols.
- Immunotherapy and potentially EZH2 inhibitors offer promising avenues for treatment in SMARCA4-deficient thoracic tumors.
